Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC 2 receptors

British Journal of Pharmacology

Volumn 161, Issue 6, 2010, Pages 1329-1342

  Tannu, S ^a   Renzetti, L ^a   Tare, N ^a   Ventre, J ^a   Lavelle, D ^a   Lin, T ^a   Morschauser, A ^a   Paciorek, J ^a   Bolin, D ^a   Michel, H ^a   Singer, L ^a   Hargaden, M ^a   Knowles, I ^b   Gardiner, P ^b   Cazzola, M ^c   Calzetta, L ^c   Matera, M ^d   Hicks, A ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b Pneumolabs Ltd   (United Kingdom)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Airway inflammation; Bronchodilator; Chronic obstructive pulmonary disease; VIP; VPAC 2 receptors

Indexed keywords

DEXAMETHASONE; LEUKOCYTE ELASTASE; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; PANCREATIC ELASTASE; RO 0251553; RO 5024118; SALBUTAMOL; SALMETEROL; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHODILATATION; BRONCHOSPASM; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; ENZYME BLOOD LEVEL; FLOW CYTOMETRY; GUINEA PIG; LEUKOCYTE ACTIVATION; LUNG INJURY; LUNG LAVAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; GUINEA PIGS; HT29 CELLS; HUMANS; LUNG; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; RATS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; SWINE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 78049401049     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00975.x     Document Type: Article

References (35)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Barnes PJ (2000). Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161: 342-344.
3. Barnes PJ (2004). Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 56: 515-548.
4. Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Fozard JR et al. (2006). In Vitro and in vivo pharmacological characterization of 5-[(R)-2-(5, 6-diethyl-indan-2-ylamino)-1-hydroxy ethyl]-8-hydroxy-1hquinolin- 2-one (indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 317: 762-770.
5. Belvisi MG, Hele DJ, Birrell MA (2004). New anti-inflammatory therapies and targets for asthma and chronic obstructive pulmonary disease. Expert Opin Ther Targets 8: 265-285.
6. Birrell MA, Wong S, Hele DJ, McCluskie K, Hardaker E, Belvisi MG (2005). Steroid-resistant inflammation in a rat model of chronic obstructive pulmonary disease is associated with a lack of nuclear factor-κB pathway activation. Am J Respir Crit Care Med 172: 74-84.
7. Birrell MA, Wong S, Hardaker EL, Catley MC, McCluskie K, Collins M et al. (2006). IκB kinase-2 independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 69: 1791-1800.
8. Bolin DR, Khan W, Michel H (2008). Preparation of novel analogs of vasoactive intestinal peptide. Patent WO2008003612 A2.
9. Bolin DR, Michalewsky J, Wasserman MA, O'Donnell M (1995). Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers 37: 57-66.
10. Corteling R, Wyss D, Trifilieff A (2002). In vivo models of lung neutrophil activation. Comparison of mice and hamsters. BMC Pharmacology 2: 1-8.
11. Cosio MG, Majo J, Cosio MG (2002). Inflammation of the Airways and Lung Parenchyma in COPD. Chest 121: 160S-165S.
12. Delgado M, Gomariz RP, Martinez C, Abad C, Leceta J (2000). Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol 30: 3236-3246.
13. Dewit D, Gourlet P, Amraoui Z, Vertongen P, Willems F, Robberecht P et al. (1998). The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. Immunol Lett 60: 57-60.
14. Farmer SG, Togo J (1990). Effects of epithelium removal on relaxation of airway smooth muscle induced by vasoactive intestinal peptide and electrical field stimulation. Br J Pharmacol 100: 73-78.
15. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M (2001). Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des 7: 89-111.
16. 2 receptor subclass. Peptides 18: 403-408.
17. Groneberg DA, Springer J, Fisher A (2001). Vasoactive Intestinal Polypeptide as Mediator of Asthma. Pulm Pharmacol Ther 14: 391-401.
18. Groneberg DA, Rabe KF, Fisher A (2006). Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. Eur J Pharmacol 533: 182-194.
19. Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG et al. (1997). Noninvasive measurements of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 156: 766-775.
20. Johnson FJ, Reynolds LJ, Toward TJ (2005). Elastolytic activity and alveolar epithelial type-1 cell damage after chronic LPS inhalation: effects of dexamethasone and rolipram. Toxicol Appl Pharmacol 207: 257-265.
21. 2 receptor agonist in patients with stable asthma. Thorax 58: 217-221.
22. Maeno T, Houghton AM, Quintero PA, Grumelli S, Owen CA, Shapiro SD (2007). CD8+ T Cells Are Required for Inflammation and Destruction in Cigarette Smoke-Induced Emphysema in Mice. J Immunol 178: 8090-8096.
23. Menghang X, Sreedharan SP, Goetzl EJ (1996). Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals. J Clin Immunol 16: 21-30.
24. 1 receptor agonist. J Biol Chem 275: 24003-24012.
25. O'Donnell M, Garippa RJ, Rinaldi N, Selig WM, Simko B, Renzetti L et al. (1994a). Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: in vitro and in vivo bronchodilator studies. J Pharmacol Exp Ther 270: 1282-1288.
26. O'Donnell M, Garippa RJ, Rinaldi N, Selig WM, Tocker JE, Tannu SA et al. (1994b). Ro 25-1553: a novel long-acting vasoactive intestinal peptide agonist. Part II: effect on in vitro and in vivo models of pulmonary anaphylaxis. J Pharmacol Exp Ther 270: 1289-1294.
27. Ohbayashi H (2002). Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs 11: 965-980.
28. Pahl A, Szelenyi I (2007). Chronic obstructive pulmonary disease (COPD). Drugs Future 32: 799-807.
29. Palmer JB, Cuss FM, Barnes PJ (1986). VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways. J Appl Physiol 61: 1322-1328.
30. Riesenfeld EP, Sullivan MJ, Thompson-Figueroa JA, Haverkamp HC, Lundblad LK, Bates JHT et al. (2010). Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease. Respir Res 11: 22-33.
31. 1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 131: 682-689.
32. 2 antagonist effects. J Pharmacol Exp Ther 306: 638-645.
33. Tam EK, Franconi GM, Nadel JA, Caughey GH (1990). Protease inhibitors potentiate smooth muscle relaxation induced by vasoactive intestinal peptide in isolated human bronchi. Am J Respir Cell Mol Biol 2: 449-452.
34. Voice JK, Dorsam G, Chan RC, Grinninger C, Kong Y, Goetzl EJ (2002). Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul Pept 109: 199-208.
35. Voice JK, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ (2003). Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell targeted type II VIP receptor transgenic mice. J Immunol 170: 308-314.